MANA Advisors LLC purchased a new position in Radius Health Inc (NASDAQ:RDUS) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,932 shares of the biopharmaceutical company’s stock, valued at approximately $347,000.
Several other institutional investors and hedge funds have also made changes to their positions in RDUS. Cubist Systematic Strategies LLC purchased a new stake in shares of Radius Health in the 3rd quarter worth approximately $110,000. Teacher Retirement System of Texas purchased a new stake in shares of Radius Health in the 4th quarter worth approximately $353,000. Daiwa Securities Group Inc. purchased a new stake in shares of Radius Health in the 3rd quarter worth approximately $385,000. Belpointe Asset Management LLC purchased a new stake in shares of Radius Health in the 3rd quarter worth approximately $474,000. Finally, UBS Asset Management Americas Inc. lifted its position in shares of Radius Health by 42.2% in the 4th quarter. UBS Asset Management Americas Inc. now owns 21,280 shares of the biopharmaceutical company’s stock worth $676,000 after purchasing an additional 6,315 shares during the period.
Radius Health Inc (NASDAQ:RDUS) opened at $35.28 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.96 and a current ratio of 5.04. Radius Health Inc has a 52 week low of $24.66 and a 52 week high of $49.16.
In other news, major shareholder Growth N. V. Biotech acquired 80,000 shares of Radius Health stock in a transaction that occurred on Friday, March 2nd. The stock was purchased at an average price of $32.52 per share, for a total transaction of $2,601,600.00. Following the purchase, the insider now directly owns 5,853,799 shares in the company, valued at approximately $190,365,543.48. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 75,000 shares of Radius Health stock in a transaction that occurred on Friday, February 9th. The shares were purchased at an average price of $34.38 per share, with a total value of $2,578,500.00. Following the purchase, the insider now owns 5,773,799 shares in the company, valued at $198,503,209.62. The disclosure for this purchase can be found here. Insiders own 15.00% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Morgan Stanley upped their price target on shares of Radius Health from $57.00 to $61.00 and gave the stock an “overweight” rating in a research report on Friday, March 2nd. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, Citigroup assumed coverage on shares of Radius Health in a research report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target for the company. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the stock. Radius Health presently has a consensus rating of “Hold” and an average target price of $52.22.
ILLEGAL ACTIVITY WARNING: “10,932 Shares in Radius Health Inc (RDUS) Acquired by MANA Advisors LLC” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3257397/10932-shares-in-radius-health-inc-rdus-acquired-by-mana-advisors-llc.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.